利培酮合并塞来昔布治疗首发精神分裂症的疗效及安全性研究

摘要

目的：探讨利培酮合并塞来昔布治疗首发精神分裂症的疗效及安全性。方法将符合诊断标准的60例首发精神分裂症患者，随机分配到对照组（30例，利培酮合并安慰剂）和研究组（30例，利培酮合并塞来昔布），研究周期为8周，塞来昔布服用剂量为600mg/d。以阳性和阴性症状量表（PANSS）评定精神症状和疗效，以汉密尔顿抑郁量表（HAMD）评定抑郁症状，以不良反应量表（TESS）和异常不自主运动量表（AIMs）评定药物不良反应和锥体外系不良反应。结果治疗8周后两组患者PANSS总分及分量表分均显著下降，与基线值相比差异有统计学意义（P均<0.05）；与对照组相比，研究组的PANSS总分、分量表减分更为明显，差异有统计学意义（P均<0.05）；两组不良反应发生率的差异无统计学意义（P均>0.05）。结论塞来昔布可增强利培酮治疗首发精神分裂症的疗效，可能是精神分裂症治疗的增效策略。%Objective To explore the effects of the combination of celecoxib and risperidone on the treatment of first-episode schizophrenia patients. Methods 60 first-episode schizophrenia patients were recruited and randomly divided into control group (treatment with risperidone and placebo) and study group(treatment with risperidone and celecoxib). The dose of celecoxib was 600 mg/d and the duration of study was 8 weeks. The efficacy and side effects were evaluated with the positive and negative symptom scale (PANSS),Hamilton Depression Scale (HAMD),treatment emergent symptom scale (TESS) and abnormal involuntary move-ment scale (AIMS). Results At the end of 8th weeks,both groups of patients showed significant decrease in total and subscales of PANSS,and significant differences were found in total and reduction rates of PANSS between two groups. Conclusion Additional treatment with celecoxib has significant positive effects on the therapeutic action of risperidone in first-episode schizophrenia pa-tients, suggesting that it might be an augmentation drug for the treatment of schizophrenia.